Given its role as master regulator of many oncogenic signals, clinical evidence of mTOR activity has been found in over half of all cancers, making it an attractive target.87 There are two main classes of ATP competitive mTOR inhibitors: the dual mTOR/PI3K inhibitors, which arise as a result of significant similarities between these kinases, and selective mTOR inhibitors, which are more selective but unlike the rapalogs can inhibit the function of both mTOR complexexes. Here, MTOR is linked to cancer.